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A 45 Year-old- Kuwaiti female with a case of IgA nephropathy (IgA N) was studied from 2002 to 2014 at 
Mubarak Hospital. The chief complaint was hematuria. In the first year she was given a conventional 
corticosteroid regimen. Her parameters at this stage are used as controls for the remainder of the study. She was 
treated with FK506 immunosuppressant capsules in the second year and vaccinated with allogeneic peripheral 
blood lymphocytes (PBL) in the third year. This study includes the following parameters: serum creatinine, 
serum albumin, IgA level, and 24-hour urine protein. In the first year the patient was only on corticosteroid, in 
the second year only FK506, and in the third year was treated only with PBL vaccination. A booster dose of 
vaccine was administered after approximately 5 years. The patient’s significant improvements after PBL 
vaccination have persisted for 9 years. The mechanism postulated for this kind of immunotherapy is induction of 
novel therapeutic antigens, including heat shock protein (HSP), that interact with autoreactive T or B cells in the 
recipient. The result is T regulatory cells (T-reg) claimed to be responsible for shifting T-cell detrimental 
function to regulatory function, hence preventing the pathological production and deposition of IgA in the 
kidney. Data accumulated from our lab, but not yet published, demonstrates that MAM14 immunotherapy 
ameliorates symptoms and signs of certain autoimmune disorders. 
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1. Introduction 
IgA Nephropathy (IgA N), also known as Berger disease, is the most common cause of primary (idiopathic) 
glomerulonephritis in the developed world [1-6]. Slow progression to end stage renal disease occurs in up to 
50% of affected patients [7]. Berger disease is a kidney disease that occurs when an antibody called 
immunoglobulin A lodges in the kidney. This results in local inflammation that, over time, may hamper the 
ability of the kidney to filter waste, excess water, and electrolytes from blood. Kidney damage may be indicated 
by blood and protein in urine, high BP, and swollen feet. IgA N usually progresses slowly over many years, but 
the course of the disease in each person is uncertain. Some people leak blood in their urine without developing 
problems, some eventually achieve complete remission, and others develop end-stage kidney failure. No cure 
exists for IgA N, but certain medications can slow its course [8]. In this case report we present a new method to 
treat IgA N, called MAM14 immunotherapy, using stressed PBL vaccination compared to other 
immunosuppressant called at one time as FK506( Tacrolimus). 
2. Materials and Methods 
A 45-year-old female presented complaining of recurrent gross hematuria shortly following any athletic 
exertion, with proteinuria. Three cohort studies of this patient were conducted. During the first year (2002) this 
patient was on a conventional corticosteroid regimen only. During the second year (2003) FK506 investigational 
immunosuppressant capsules from the University of Pittsburgh Medical Center were administered. In 2004 
stressed allogeneic lymphocyte vaccination was implemented. The mechanism postulated for MAM14 
immunotherapy is that culturing lymphocytes in vitro allow induction of novel, therapeutic antigens , including 
heat shock proteins . These therapeutic antigens assist the autoreactive T cell to shift to regulatory cell. Regulate 
the autoimmune attack. Lead to homeostasis and was further explored in 2013 [9]. 
3. Results 
Results are depicted as four Figures. 
 
Figure 1: Serum creatinine. Analyzed: One-way ANOVA data, P value < 0.0001. 
Figure 1 shows that Serum creatinine improved dramatically using FK506. Also Allogeneic PBL improved 
serum creatinine significantly. But the difference in this article that is no side effect noted on MAM14 
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vaccination for 9 years. However, FK506 is a drug with side effects. 
 
Figure 2:   Serum albumin, Analyzed: One-way ANOVA data, P value < 0.0001. 
Figure 2 shows that Serum albumin concentration improved with FK506 and PBL vaccination (MAM14) the 
difference is the safety of MAM14 and long lasting for 9 years. 
 
Figure 3:   IgA level, Analyzed: One-way ANOVA data, P value < 0.0001. 
Figure 3 shows that IgA levels dropped dramatically by FK506 and by PBL vaccination. Normal concentration 
is 0.8-2.9 g/L 
.  
Figure 4: 24 hour urine protein, Analyzed: One-way ANOVA data, P value < 0.0001. 
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Figure 4 shows that Urine protein was reduced significantly by FK506 for one year and reduced significantly by 
PBL vaccination for 9 years. The difference is the leukocyte vaccination is safe and FK 506 is a drug with side 
effects. 
The administration of a conventional corticosteroid regimen to this patient resulted in some short-term 
improvements in the parameters studied. FK506 immunosuppressant caused significant improvements for a 
short period. MAM14 data showed that after administering the MAM14 immunotherapy protocol remarkable 
improvements in all parameters tested in this patient (serum creatinine, serum albumin, IgA levels, and 24-hour 
urine proteins) were sustained from the third year onward for as long as 9 years. A booster dose was given after 
5 years. 
4. Conclusion 
We postulate a mechanism of action in the MAM14 protocol in which culturing donor lymphocytes induces 
expression of heat shock proteins (9) that interact with activated or autoreactive memory T or B cells in the 
recipient. The result is a suppressor cell (T-reg) that responds to self-antigens by expression of 
immunosuppressive cytokines, principally Th2-associated (IL-10 and TGFB), downregulating expression of 
Th1-associated cytokines (IL-2; IL-12 and IFN-GAMA; and IL-1B, TNF-ALFA, and IL6). The outcome is a 
suppression of autoimmune attacks on host tissue. T-reg in turn modifies production of IgA through T-B cell 
interactions. An imbalance of type 1 and type 2 T cell subsets has been proposed as an explanation for the 
dysregulated IgA responses seen in IgA nephropathy. In addition, there is provisional work suggesting that types 
1 and 2 cytokines differentially affect IgA 1 o-glycosylation [8]. 
The regulatory T cells formerly known as suppressor T cells are a subpopulation of T cells that modulate the 
immune system, maintain tolerance to self-antigens, and abrogate autoimmune disease. These cells generally 
suppress or downregulate induction and proliferation of effector T cells. Additional regulatory T cells known as 
T-reg 17 cells have recently been identified. Mouse models have suggested that modulation of T-regs can 
positively affect autoimmune disease and cancer, and facilitate organ transplant. 
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